Surface Plasmon Resonance (SPR)
SPR is a label-free analytical technique to characterize therapeutic antibody candidates or other biomolecules. It measures the real-time interaction between antibodies and their targets, providing binding kinetics (Ka and Kd) and affinity. When coupled with functional cell-based assays, binding analysis of an antibody and its target offers insights into therapeutic candidates’ potential function and MoA.
Tap Into Rapid and Consistent Binding Assessment
At Eurofins Discovery, we have extensive biotherapeutics experience to ensure that your biologics are well-characterized and meet regulatory safety and efficacy guidelines. Our SPR assays are optimized to ensure consistent results with rapid turn-around times, and our dedicated scientific team provides essential protein binding data. We also provide complementing services, such as protein production, functional assessment, and antibody optimization, for a multi-faceted approach to your biotherapeutics development program.
Binding Affinity Measurement
SPR enables the measurement of association and dissociation rates for protein-protein interactions, enabling the determination of binding affinity, also known as the dissociation constant or Kd. These data shed light on the nature of protein binding and allows for ranking and downstream optimization of promising leads. Eurofins Discovery has high-throughput SPR capabilities for rapid binding affinity measurement and scientific expertise for more informed lead selection.
Antigen Specificity
The specificity of an antibody candidate can be measured by assessing binding to the intended target antigen compared to a non-target antigen using SPR. Specificity assays could identify potential off-target effects and downstream safety issues. Our antibody characterization experts can help perform critical specificity assessments, providing the information you need for successful lead selection, optimization, and development.
FcγR, FcRn, and C1q Binding Affinity and Kinetics
Measuring FcγR, FcRn, and C1q binding affinity and kinetics provides a better understanding of a therapeutic antibody candidate’s effector function and interactions with the immune system. This data can help optimize how a candidate modulates antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or antibody-dependent cellular phagocytosis (ADCP) to improve therapeutic efficacy or avoid undesirable safety issues. At Eurofins Discovery, we couple these binding/specificity assessments with cytotoxicity assays to ensure you have comprehensive functional and binding data to meet regulatory guidelines and inform downstream optimization efforts.
Affinity and Epitope Binning
Affinity and epitope binning is a technique for measuring how tightly and where a therapeutic antibody binds to its target antigen. These SPR-based methods provide comprehensive characterization data, allowing the selection of diverse candidates, guide additional optimization efforts, and increase the likelihood of clinical success. We can help you perform rapid affinity and epitope binning along with expert direction for ranking and prioritizing which candidates to move forward.
Species Cross-Reactivity
SPR can be used to assess whether a therapeutic antibody candidate binds the target antigen from different species, including mice, rats, monkeys, or humans. These data enable the informed selection of animal models for toxicity assessment and can help identify off-target interactions, supporting more efficient translation into clinical testing.
